| Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas Y Jiao, PJ Killela, ZJ Reitman, BA Rasheed, CM Heaphy, RF de Wilde, ... Oncotarget 3 (7), 709, 2012 | 708 | 2012 |
| Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas PJ Killela, CJ Pirozzi, P Healy, ZJ Reitman, E Lipp, BA Rasheed, R Yang, ... Oncotarget 5 (6), 1515, 2014 | 304 | 2014 |
| The implications of IDH mutations for cancer development and therapy CJ Pirozzi, H Yan Nature Reviews Clinical Oncology, 1-17, 2021 | 265 | 2021 |
| KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation C Guo, LH Chen, Y Huang, CC Chang, P Wang, CJ Pirozzi, X Qin, X Bao, ... Oncotarget 4 (11), 2144, 2013 | 159 | 2013 |
| Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target C Guo, CJ Pirozzi, GY Lopez, H Yan Current opinion in neurology 24 (6), 648, 2011 | 110 | 2011 |
| The genetic landscape of anaplastic astrocytoma PJ Killela, CJ Pirozzi, ZJ Reitman, S Jones, BA Rasheed, E Lipp, ... Oncotarget 5 (6), 1452, 2014 | 83 | 2014 |
| Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation R Yang, LH Chen, LJ Hansen, AB Carpenter, CJ Moure, H Liu, CJ Pirozzi, ... Cancer research 77 (22), 6097-6108, 2017 | 57 | 2017 |
| Mutant IDH1 disrupts the mouse subventricular zone and alters brain tumor progression CJ Pirozzi, AB Carpenter, MS Waitkus, CY Wang, H Zhu, LJ Hansen, ... Molecular Cancer Research 15 (5), 507-520, 2017 | 51 | 2017 |
| Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1R132H-induced metabolic liabilities MS Waitkus, CJ Pirozzi, CJ Moure, BH Diplas, LJ Hansen, AB Carpenter, ... Cancer research 78 (1), 36-50, 2018 | 46 | 2018 |
| MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation LJ Hansen, R Sun, R Yang, SX Singh, LH Chen, CJ Pirozzi, CJ Moure, ... Cancer research 79 (13), 3383-3394, 2019 | 44 | 2019 |
| Mutant IDH1 is required for IDH1 mutated tumor cell growth G Jin, CJ Pirozzi, LH Chen, GY Lopez, CG Duncan, J Feng, I Spasojevic, ... Oncotarget 3 (8), 774, 2012 | 41 | 2012 |
| Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe Y Liu, AB Carpenter, CJ Pirozzi, H Yuan, MS Waitkus, Z Zhou, L Hansen, ... Nanotechnology 30 (27), 275101, 2019 | 32 | 2019 |
| Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors ZJ Reitman, CJ Pirozzi, H Yan Acta neuropathologica 126 (6), 789-792, 2013 | 30 | 2013 |
| Releasing the block: setting differentiation free with mutant IDH inhibitors CJ Pirozzi, ZJ Reitman, H Yan Cancer cell 23 (5), 570-572, 2013 | 26 | 2013 |
| CRISPR editing of mutant IDH1 R132H induces a CpG methylation-low state in patient-derived glioma models of G-CIMP CJ Moure, BH Diplas, LH Chen, R Yang, CJ Pirozzi, Z Wang, I Spasojevic, ... Molecular Cancer Research 17 (10), 2042-2050, 2019 | 25 | 2019 |
| TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist C Xu, H Liu, CJ Pirozzi, LH Chen, PK Greer, BH Diplas, L Zhang, ... Acta neuropathologica communications 9 (1), 1-12, 2021 | 13 | 2021 |
| Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization C Du, SW Li, SX Singh, K Roso, MA Sun, CJ Pirozzi, R Yang, JL Li, Y He Molecular Cancer Research, 2021 | 10 | 2021 |
| Preclinical Immunotherapeutic Animal Models for Brain Tumors V Chandramohan, L Sanchez-Perez, Y He, CJ Pirozzi, KL Congdon, ... Translational Immunotherapy of Brain Tumors, 111-147, 2017 | 4 | 2017 |
| Tumor-Specific Mutations in Gliomas and Their Implications for Immunotherapy CJ Pirozzi, AB Carpenter, T Hennika, OJ Becher, H Yan Translational Immunotherapy of Brain Tumors, 83-107, 2017 | 3 | 2017 |
| Glioma Research in the era of medical big data F Wang, CJ Pirozzi, X Li Cancer Translational Medicine 4 (4), 95, 2018 | 2 | 2018 |
